Effect of lanreotide autogel/depot (LAN) on tumor growth rate (TGR) in patients with metastatic bronchopulmonary neuroendocrine tumors (BP-NETs): Exploratory data from the phase 3 SPINET study

被引：0
|
作者：
Baudin, E. [1 ]
Hoersch, D. [2 ]
Singh, S. [3 ]
Caplin, M. [4 ]
Ferone, D. [5 ]
Wolin, E. [6 ]
Capdevila, J. [7 ]
Buikhuisen, W. [8 ]
Raderer, M. [9 ]
Houchard, A. [10 ]
Thanh, Truong X. M. [10 ]
Reidy-Lagunes, D. [11 ]
机构：
[1] Gustave Roussy Inst Cancerol, Villejuif, France
[2] Zent Klin Bad Berka GmbH, Bad Berka, Germany
[3] Sunnybrook HSC, Sunnybrook Odette Canc Ctr, Med Oncol & Hematol, Toronto, ON, Canada
[4] Royal Free Hosp, Sch Med, Neuroendocrine Tumour Unit, London, England
[5] Univ Genoa, Neuroendocrine Tumour Unit, Dept Internal Med & Med Specialties, Genoa, Italy
[6] Cedars Sinai Med Ctr, Samuel Oschin Comprehens Canc Inst, Los Angeles, CA 90048 USA
[7] Vall dHebron Univ Hosp, Dept Med Oncol, Vall dHebron Inst Oncol VHIO, Barcelona, Spain
[8] Netherlands Canc Inst, Dept Thorax Oncol, Amsterdam, Netherlands
[9] Med Univ Vienna, Vienna, Austria
[10] Ipsen, Boulogne Billancourt, France
[11] Mem Sloan Kettering Canc Ctr, New York, NY USA
来源：
JOURNAL OF NEUROENDOCRINOLOGY | 2022年 / 34卷
关键词：
bronchopulmonary neuroendocrine tumor; lanreotide autogel/depot; spinet; tumor growth rate; typical/atypical carcinoid;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
I03
引用
收藏
页码：165 / 165
页数：1
相关论文
共 50 条
  • [41] Safety and Efficacy of 14-Day Dosing Interval of Lanreotide Autogel/ Depot (LAN) for Patients with Pancreatic or Midgut Neuroendocrine Tumours (NETs) Progressing on LAN Every 28 Days: The Prospective, Open-label, International, Phase 2 CLARINET FORTE Study
    Pavel, M.
    Dromain, C.
    Majdi, A.
    Houchard, A.
    NEUROENDOCRINOLOGY, 2017, 105 : 204 - 204
  • [42] Progression-Free Survival (PFS) and Tumor Growth with Lanreotide Autogel (LAN) in Patients (Pts) with Enteropancreatic NETs: Results from CLARINET, a Randomized, Double-Blind, Placebo (Pbo)-Controlled Study
    Caplin, M.
    Ruszniewski, P.
    Pavel, M.
    Cwikla, J.
    Phan, A.
    Raderer, M.
    Sedlackova, E.
    Cadiot, G.
    Wall, L.
    Rindi, G.
    Langley, A.
    Blumberg, J.
    NEUROENDOCRINOLOGY, 2014, 99 (3-4) : 270 - 270
  • [43] Design of a Phase 3, International, Prospective, Randomized, Double-Blind, Placebo (PBO) Controlled Study Assessing Efficacy and Safety of Lanreotide Autogel/Depot (LAN) 120 mg in Patients with Well-Differentiated, Advanced Typical and Atypical Lung NETs
    Reidy-Lagunes, D.
    Kulke, M.
    Wolin, E.
    Mirakhur, B.
    Massien, C.
    Caplin, M.
    Baudin, E.
    NEUROENDOCRINOLOGY, 2016, 103 : 118 - 118
  • [44] Pre-Treatment Tumor Growth Rate (TGR0) in Patients Diagnosed with Well-Differentiated Neuroendocrine Tumors (NETs) Treated with Systemic Therapies: Subgroup Analysis of the GREPONET Study
    Crona, J.
    Lamarca, A.
    Ronot, M.
    Opalinska, M.
    Lopez Lopez, C.
    Pezzutti, D.
    Vidal Trueba, H.
    Carvhalo, L.
    de Mestier, L.
    Najran, P.
    Pavel, M.
    Dromain, C.
    NEUROENDOCRINOLOGY, 2018, 106 : 171 - 171
  • [45] Lanreotide depot (LAN) for symptomatic control of carcinoid syndrome (CS) in neuroendocrine tumor (NET) patients previously responsive to octreotide (OCT): Subanalysis of patient-reported symptoms from the phase III elect study.
    Fisher, George A.
    Pommier, Rodney F.
    Wolin, Edward M.
    Kunz, Pamela L.
    Liyanage, Nilani
    Lowenthal, Susan W. Pitman
    Mirakhur, Beloo
    Shaheen, Montaser F.
    Vinik, Aaron
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [46] Efficacy of lanreotide depot (LAN) for symptomatic control of carcinoid syndrome (CS) in patients with neuroendocrine tumor (NET) previously responsive to octreotide (OCT): Subanalysis of patient-reported symptoms from the phase III ELECT study.
    Pommier, Rodney F.
    Fisher, George A.
    Wolin, Edward M.
    Kunz, Pamela L.
    Liyanage, Nilani
    Lowenthal, Susan W. Pitman
    Mirakhur, Beloo
    Shaheen, Montaser F.
    Vinik, Aaron
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [47] u Effect of lanreotide depot (LAN) on 5-hydroxyindoleacetic acid (5HIAA) and chromogranin A (CgA) in gastroenteropa ncreatic neuroendocrine (GEP NET) tumors: Correlation with tumor response and progression-free survival (PFS) from the phase III CLARINET study.
    Phan, Alexandria T.
    Wolin, Edward M.
    Liyanage, Nilani
    Mirakhur, Beloo
    Pitman, Susan W.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [48] Design of a phase 3, international multicenter, prospective, randomized, double-blind, placebo controlled study assessing the efficacy and safety of lanreotide depot 120 mg in patients with well-differentiated, advanced typical and atypical lung neuroendocrine tumors (NETs)
    Reidy-Lagunes, Diane
    Wolin, Edward M.
    Lowenthal, Susan Pitman
    Cox, David
    Kulke, Matthew H.
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (02) : S31 - S31
  • [49] Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients With Metastatic Neuroendocrine Midgut Tumors: A Report From the PROMID Study Group
    Rinke, Anja
    Mueller, Hans-Helge
    Schade-Brittinger, Carmen
    Klose, Klaus-Jochen
    Barth, Peter
    Wied, Matthias
    Mayer, Christina
    Aminossadati, Behnaz
    Pape, Ulrich-Frank
    Blaeker, Michael
    Harder, Jan
    Arnold, Christian
    Gress, Thomas
    Arnold, Rudolf
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (28) : 4656 - 4663
  • [50] Placebo-Controlled, Double-Blind, Prospective, Randomized Study of the Effect of Octreotide LAR in the Control of Tumor Growth in Patients with Metastatic Neuroendocrine Midgut Tumors: A Report from the PROMID Study Group
    Baminger, Helmut
    AUSTRIAN JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM, 2009, 2 (01): : 29 - 29
12345